Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity

Journal of Experimental Medicine

Volumn 215, Issue 3, 2018, Pages 877-893

  Perry, Curtis J ^a   Muñoz Rojas, Andrés R ^b   Meeth, Katrina M ^a   Kellman, Laura N ^b   Amezquita, Robert A ^a,c   Thakral, Durga ^a   Du, Victor Y ^a   Wang, Jake Xiao ^a   Damsky, William ^a   Kuhlmann, Alexandra L ^a   Sher, Joel W ^b   Bosenberg, Marcus ^a   Miller Jensen, Kathryn ^b   Kaech, Susan M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; FGK 45; GAMMA INTERFERON; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; INTERLEUKIN 12; INTERLEUKIN 6; PLX 6134; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD40 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; UPREGULATION; AGONISTS; ANIMAL; BONE MARROW CELL; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; PHENOTYPE; SURVIVAL ANALYSIS; T LYMPHOCYTE;

ANIMALS; CD40 ANTIGENS; CELL PROLIFERATION; IMMUNOTHERAPY; INFLAMMATION; INTERFERON-GAMMA; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MYELOID CELLS; NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RNA, MESSENGER; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85042854291     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20171435     Document Type: Article

References (44)

1. Amir, A.D., K.L. Davis, M.D. Tadmor, E.F. Simonds, J.H. Levine, S.C. Bendall, D.K. Shenfeld, S. Krishnaswamy, G.P. Nolan, and D. Pe'er. 2013. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 31:545-552. https ://doi .org /10 .1038 /nbt .2594
2. Anders, S., D.J. McCarthy, Y. Chen, M. Okoniewski, G.K. Smyth, W. Huber, and M.D. Robinson. 2013. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat. Protoc. 8:1765-1786. https ://doi .org /10 .1038 /nprot .2013 .099
3. Beatty, G.L., E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, W. Sun, R.D. Huhn, W. Song, D. Li, L.L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 331:1612-1616. https ://doi .org /10 .1126 / science .1198443
4. Bhadra, R., J.P. Gigley, and I.A. Khan. 2011. Cutting edge: CD40-CD40 ligand pathway plays a critical CD8-intrinsic and-extrinsic role during rescue of exhausted CD8 T cells. J. Immunol. 187:4421-4425. https ://doi .org /10 .4049 /jimmunol .1102319
5. Cassier, P.A., H. Gelderblom, S. Stacchiotti, D. Thomas, R.G. Maki, J.R. Kroep, W.T. van der Graaf, A. Italiano, B. Seddon, J. Dômont, et al. 2012. Efficacy of imatinib mesylate for the treatment of locally advanced and/ or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 118:1649-1655. https ://doi .org /10 .1002 /cncr .26409
6. Dankort, D., D.P. Curley, R.A. Cartlidge, B. Nelson, A.N. Karnezis, W.E.J. Damsky Jr., M.J. You, R.A. DePinho, M. McMahon, and M. Bosenberg. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41:544-552. https ://doi .org /10 .1038 /ng .356
7. Deryugina, E.I., E. Zajac, A. Juncker-Jensen, T.A. Kupriyanova, L. Welter, and J.P. Quigley. 2014. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia. 16:771-788. https ://doi .org /10 .1016 /j .neo .2014 .08 .013
8. Díaz-Valdés, N., M. Basagoiti, J. Dotor, F. Aranda, I. Monreal, J.I. Riezu-Boj, F. Borrás-Cuesta, P. Sarobe, and E. Feijoó. 2011. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res. 71:812-821. https ://doi .org /10 .1158 /0008-5472 .CAN-10-2698
9. Flaherty, K.T., J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, et al. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367:1694-1703. https ://doi .org /10 .1056 /NEJMoa1210093
10. Flaherty, K.T., S.J. Lee, F. Zhao, L.M. Schuchter, L. Flaherty, R. Kefford, M.B. Atkins, P. Leming, and J.M. Kirkwood. 2013. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J. Clin. Oncol. 31:373-379. https ://doi .org /10 .1200 /JCO .2012 .42 .1529
11. Hauschild, A., J.-J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C.U. Blank, W.H. Miller Jr., E. Kaempgen, et al. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380:358-365. https ://doi .org /10 .1016 /S0140-6736(12)60868-X
12. Ho, P.-C., K.M. Meeth, Y.-C. Tsui, B. Srivastava, M.W. Bosenberg, and S.M. Kaech. 2014. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res. 74:3205-3217. https :// doi .org /10 .1158 /0008-5472 .CAN-13-3461
13. Hoves, S., C.-H. Ooi, C. Wolter, H. Sade, S. Bissinger, M. Schmittnaegel, O. Ast, A.M. Giusti, K. Wartha, V. Runza, et al. 2018. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J. Exp. Med. https ://doi .org /10 .1084 /jem .20171440
14. Hussein, M.R. 2006. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int. J. Exp. Pathol. 87:163-176. https ://doi .org /10 .1111 /j .1365-2613 .2006 .00478 .x
15. Joyce, J.A., and J.W. Pollard. 2009. Microenvironmental regulation of metastasis. Nat. Rev. Cancer. 9:239-252. https ://doi .org /10 .1038 / nrc2618
16. Kammertoens, T., C. Friese, A. Arina, C. Idel, D. Briesemeister, M. Rothe, A. Ivanov, A. Szymborska, G. Patone, S. Kunz, et al. 2017. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature. 545:98-102. https ://doi .org /10 .1038 /nature22311
17. Kaneda, M.M., K.S. Messer, N. Ralainirina, H. Li, C.J. Leem, S. Gorjestani, G. Woo, A.V. Nguyen, C.C. Figueiredo, P. Foubert, et al. 2016. PI3Kγ is a molecular switch that controls immune suppression. Nature. 539:437-442. https ://doi .org /10 .1038 /nature19834
18. Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, et al. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203:871-881. https ://doi .org /10 .1084 /jem .20050930
19. Larkin, J., V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, et al. 2015. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373:23-34. https ://doi .org /10 .1056 / NEJMoa1504030
20. Levine, J.H., E.F. Simonds, S.C. Bendall, K.L. Davis, A.D. Amir, M.D. Tadmor, O. Litvin, H.G. Fienberg, A. Jager, E.R. Zunder, et al. 2015. Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell. 162:184-197. https ://doi .org /10 .1016 /j .cell .2015 .05 .047
21. Li, F., and J.V. Ravetch. 2011. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 333:1030-1034. https ://doi .org /10 .1126 /science .1206954
22. Lu, Y., J.J. Chen, L. Mu, Q. Xue, Y. Wu, P.H. Wu, J. Li, A.O. Vortmeyer, K. Miller-Jensen, D. Wirtz, and R. Fan. 2013. High-throughput secretomic analysis of single cells to assess functional cellular heterogeneity. Anal. Chem. 85:2548-2556. https ://doi .org /10 .1021 /ac400082e
23. Maltby, S., N.G. Hansbro, H.L. Tay, J. Stewart, M. Plank, B. Donges, H.F. Rosenberg, and P.S. Foster. 2014. Production and differentiation of myeloid cells driven by proinflammatory cytokines in response to acute pneumovirus infection in mice. J. Immunol. 193:4072-4082. https ://doi .org /10 .4049 /jimmunol .1400669
24. Mitchem, J.B., D.J. Brennan, B.L. Knolhoff, B.A. Belt, Y. Zhu, D.E. Sanford, L. Belaygorod, D. Carpenter, L. Collins, D. Piwnica-Worms, et al. 2013. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73:1128-1141. https ://doi .org /10 .1158 /0008-5472 .CAN-12-2731
25. Ngiow, S.F., K.M. Meeth, K. Stannard, D.S. Barkauskas, G. Bollag, M. Bosenberg, and M.J. Smyth. 2016. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRA FV600E melanoma. OncoImmunology. 5:e1089381. https ://doi .org /10 .1080 /2162402X .2015 .1089381
26. Piccolo, V., A. Curina, M. Genua, S. Ghisletti, M. Simonatto, A. Sabò, B. Amati, R. Ostuni, and G. Natoli. 2017. Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk. Nat. Immunol. 18:530-540. https ://doi .org /10 .1038 /ni .3710
27. Pollard, J.W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 4:71-78. https ://doi .org /10 .1038 /nrc1256
28. Pyonteck, S.M., L. Akkari, A.J. Schuhmacher, R.L. Bowman, L. Sevenich, D.F. Quail, O.C. Olson, M.L. Quick, J.T. Huse, V. Teijeiro, et al. 2013. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19:1264-1272. https ://doi .org /10 .1038 /nm .3337
29. Qian, B.-Z., and J.W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell. 141:39-51. https ://doi .org /10 .1016 /j .cell .2010 .03 .014
30. Qiao, Y., E.G. Giannopoulou, C.H. Chan, S.-H. Park, S. Gong, J. Chen, X. Hu, O. Elemento, and L.B. Ivashkiv. 2013. Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. Immunity. 39:454-469. https ://doi .org /10 .1016 /j .immuni .2013 .08 .009
31. Ries, C.H., M.A. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, F. Rey-Giraud, L.P. Pradel, F. Feuerhake, I. Klaman, et al. 2014. Targeting tumorassociated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 25:846-859. https ://doi .org /10 .1016 /j .ccr .2014 .05 .016
32. Ryder, M., M. Gild, T.M. Hohl, E. Pamer, J. Knauf, R. Ghossein, J.A. Joyce, and J.A. Fagin. 2013. Genetic and pharmacological targeting of CSF-1/ CSF-1R inhibits tumor-associated macrophages and impairs BRAFinduced thyroid cancer progression. PLoS One. 8:e54302. https ://doi .org /10 .1371 /journal .pone .0054302
33. Tamoutounour, S., M. Guilliams, F. Montanana Sanchis, H. Liu, D. Terhorst, C. Malosse, E. Pollet, L. Ardouin, H. Luche, C. Sanchez, et al. 2013. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity. 39:925-938. https ://doi .org /10 .1016 /j .immuni .2013 .10 .004
34. Tumeh, P.C., C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568-571. https ://doi .org /10 .1038 /nature13954
35. Ugel, S., F. De Sanctis, S. Mandruzzato, and V. Bronte. 2015. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumorassociated macrophages. J. Clin. Invest. 125:3365-3376. https ://doi .org /10 .1172 /JCI80006
36. Wang, J., C.J. Perry, K. Meeth, D. Thakral, W. Damsky, G. Micevic, S. Kaech, K. Blenman, and M. Bosenberg. 2017. UV-induced somatic mutations elicit a functional T cell response in the YUM MER1.7 mouse melanoma model. Pigment Cell Melanoma Res. 30:428-435. https ://doi .org /10 .1111 /pcmr .12591
37. Wiehagen, K.R., N.M. Girgis, D.H. Yamada, A.A. Smith, S.R. Chan, I.S. Grewal, M. Quigley, and R.I. Verona. 2017. Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity. Cancer Immunol. Res. 5:1109-1121. https ://doi .org /10 .1158 /2326-6066 .CIR-17-0258
38. Winograd, R., K.T. Byrne, R.A. Evans, P.M. Odorizzi, A.R. Meyer, D.L. Bajor, C. Clendenin, B.Z. Stanger, E.E. Furth, E.J. Wherry, and R.H. Vonderheide. 2015. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol. Res. 3:399-411. https ://doi .org /10 .1158 /2326-6066 .CIR-14-0215
39. Woo, S.-R., L. Corrales, and T.F. Gajewski. 2015. Innate immune recognition of cancer. Annu. Rev. Immunol. 33:445-474. https ://doi .org /10 .1146 / annurev-immunol-032414-112043
40. Wynn, T.A., A. Chawla, and J.W. Pollard. 2013. Macrophage biology in development, homeostasis and disease. Nature. 496:445-455. https ://doi .org /10 .1038 /nature12034
41. Xu, J., J. Escamilla, S. Mok, J. David, S. Priceman, B. West, G. Bollag, W. McBride, and L. Wu. 2013. CSF1R signaling blockade stanches tumorinfiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73:2782-2794. https ://doi .org /10 .1158 /0008-5472 .CAN-12-3981
42. Xue, Q., Y. Lu, M.R. Eisele, E.S. Sulistijo, N. Khan, R. Fan, and K. Miller-Jensen. 2015. Analysis of single-cell cytokine secretion reveals a role for paracrine signaling in coordinating macrophage responses to TLR4 stimulation. Sci. Signal. 8:ra59. https ://doi .org /10 .1126 /scisignal .aaa2155
43. Youn, J.-I., S. Nagaraj, M. Collazo, and D.I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791-5802. https ://doi .org /10 .4049 /jimmunol .181 .8 .5791
44. Zhao, J., Z. Lv, F. Wang, J. Wei, Q. Zhang, S. Li, F. Yang, X. Zeng, X. Wu, and Z. Wu. 2013. Ym1, an eosinophilic chemotactic factor, participates in the brain inflammation induced by Angiostrongylus cantonensis in mice. Parasitol. Res. 112:2689-2695. https ://doi .org /10 .1007 /s00436-013-3436-x